Skip to content
Screener

Rhythm Pharmaceuticals, Inc. RYTM Short-Term Investments

Short-Term Investments at other companies

Aardvark Therapeutics, Inc. logo
Aardvark Therapeutics, Inc.AARD
$28.76M-76.9%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$484.85M-40.4%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
$107.56M+40.7%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$1.05B+40.1%
Arrowhead Research logo
Arrowhead ResearchARWR
$1.6B+75.0%
MBX Biosciences, Inc. logo
MBX Biosciences, Inc.MBX
$394.76M+87.2%

Other financials

Income statement

See full
Revenue$60.1M+83.8%
Gross profit$53.0M+82.3%
Operating income-$52.4M-11.4%
Net income-$55.6M-12.4%
EPS (diluted)-$0.83-2.5%

Balance sheet

See full
Cash & equivalents$62.1M-41.4%
Total debt$112.3M-1.1%
Total equity$122.9M+549%
Total assets$442.3M+14.4%

Cash flow

See full
Operating cash flow-$44.2M-9.5%
CapEx$238.3K
Free cash flow-$29.2M-2.4%

Valuation

See full
Market cap$7.62B+27.5%
Enterprise value$7.67B+28.8%
P/S35.1×-3.2×

Profitability

See full
Gross margin89.4%-0.2pp
Operating margin-90.9%-19.8pp
Net margin-93.3%-18.2pp
FCF margin-61.5%-14.1pp

Returns & leverage

See full
Return on equity-285.8%-68.9pp
Debt / equity0.9×-5.1×
Current ratio4.2×+0.9×

Where this comes from

Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShortTermInvestments.

The source filing: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-030549
Line itemMarch 31,2026December 31,2025
Assets
Current assets:
Cash and cash equivalents$62,137$54,301
Short-term investments278,488334,648
Accounts receivable, net34,19226,081
Inventory28,65125,753
Prepaid expenses and other current assets26,62226,133
Total current assets430,090466,916

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Rhythm Pharmaceuticals, Inc.'s short-term investments?
Rhythm Pharmaceuticals, Inc. (RYTM) reported short-term investments of $278.49M in Q1 2026.
How has Rhythm Pharmaceuticals, Inc.'s short-term investments changed year-over-year?
Rhythm Pharmaceuticals, Inc.'s short-term investments increased by 33.6% year-over-year, from $208.39M to $278.49M.
What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s short-term investments?
Over 5 years (2020 to 2025), Rhythm Pharmaceuticals, Inc.'s short-term investments has grown at a 36.0% compound annual growth rate (CAGR), from $71.94M to $334.65M.
What does short-term investments mean?
Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.

Ask your AI about Rhythm Pharmaceuticals, Inc.'s short-term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude